Pachychoroid spectrum disease

Borooah, Shyamanga; Sim, Peng Yong; Phatak, Sumita; Moraes, Gabriella; Wu, Chris Y.; Cheung, Chui Ming Gemmy; Pal, Bishwanath; Bujarborua, Dhiren

doi:10.1111/aos.14683

Cited by 61 publications

(81 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Focal or diffuse thickening of the choroid, dilated state layer vessels (pachy-veins), thinning in the Sattler layer and choriocapillaris, and choroidal hyperpermeability constitute pachychoroid spectrum diseases (such as central serous chorioretinopathy, polypoidal choroidal vasculopathy) characteristics. 36 In this study, we found that the choroidal parameters we obtained during the three-month follow-up of mirabegron mimicked the choroidal findings in pachychoroid spectrum diseases. We believe that the significant thinning of the choriocapillaris/Sattler's layer complex (SCVL) in the second-and third-month period and the significant thickening of the Haller's layer (LCVL) in the firstand second-month periods compared to the baseline points toward β3-adrenergic blockage as a new treatment target.…”

Section: Discussionsupporting

confidence: 63%

Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity

Topçuoğlu¹,

Aslan²

2021

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

To determine the effect of the new β 3 -agonist (mirabegron), which is used for overactive bladder (OAB) treatment, on central retinal thickness (CRT) and choroidal vascularity.MATERIAL AND METHODS. The 26 eyes of 26 cases using 50 mg tablet mirabegron once per day for OAB were included in this prospective case control study. The CRT, choroidal thickness (ChT), and choroidal vascularity were measured at baseline, week 1 (W1), month 1 (M1), month 2 (M2), and month 3 (M3). Subfoveal ChT measurement included the total subfoveal choroidal thickness (SFCT), and the small and large choroidal vessel layer (SCVL and LCVL) thickness. The total choroidal area (TCA), lumen area (LA), stromal area (SA), stroma/lumen ratio, and choroidal vascularity index (CVI) were measured with the Image-J software. RESULTS.The largest SFCT increase compared to baseline was at M1 (26.8 ± 40.8 μm, P = 0.001). The subfoveal SCVL thickness showed a significant decrease at M2 and M3 (−6.0 ± 8.9 μm, P = 0.002; −7.8 ± 13.4 μm, P = 0.046, respectively). LCVL thickness showed a significant increase at W1, M1, and M2, with the largest at M1. CVI showed a significant increase at M1, M2, and M3 (P < 0.05 for all). The TCA, LA, and SA showed a significant increasing trend at all follow-up periods. LA/SA decreased at W1 because of stromal expansion but increased at M3 with more prominent vascular dilatation. CRT values showed no significant change. CONCLUSIONS.Mirabegron had a significant effect on choroidal thickness. Choroidal vascular response is in the form of narrowing in the choriocapillaris and enlargement in the Haller's layer.

show abstract

Section: Discussionsupporting

confidence: 63%

Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity

Topçuoğlu¹,

Aslan²

2021

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Recently, it has been suggested that pachychoroid neovasculopathy (PNV) is a type 1 (sub-retinal pigment epithelium [RPE]) CNV characterized by underlying dilated choroidal vessels, attenuation of choriocapillaris, and thickened choroid 2 . PNV has been proposed as one of the pachychoroid-driven spectrum of diseases, including pachychoroid pigment epitheliopathy (PPE) 3 , central serous chorioretinopathy (CSC), and polypoidal choroidal vasculopathy/aneurysmal type 1 macular neovascularization (PCV/AT1) 2 , 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Yoon

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). Forty-one eyes with PNV, 68 eyes with PCV/AT1, and 56 eyes with typical nAMD were retrospectively included for analysis. All patients were treatment-naïve and received a three-monthly loading injection of anti-VEGF, followed by further injections, as required. The visual and anatomical outcomes after treatment were evaluated up to 36 months from baseline. No significant intergroup difference was found in terms of best-corrected visual acuity (BCVA) and changes in central foveal thickness at 12, 24, and 36 months after the baseline. In addition, no significant difference was found between the groups regarding the proportions of improved or worsened (increased or decreased more than 3-lines) visual acuity. However, the PNV group participants received significantly fewer anti-VEGF injections (11.7 ± 6.9) than those in the PCV/AT1 (12.4 ± 7.0; P = 0.031) and typical nAMD groups (13.2 ± 7.4; P = 0.016). The incidence of macular atrophy (MA) development was also significantly lower for the PNV (4/41 eyes, 9.8%) than the typical nAMD (15/56 eyes, 26.8%; P = 0.033) eyes. There was no significant difference between PNV, PCV/AT1, and typical nAMD regarding visual acuity improvement after anti-VEGF treatment over 36 months. However, the number of injections for PNV was significantly lower compared to that for PCV/AT1 and typical nAMD, and the incidence of MA development was significantly lower than in typical nAMD.

show abstract

“…CVH was more commonly seen in the eyes with pachychoroid 42 , but it also occurred in the PCV and fellow eyes. [43][44][45][46][47][48] A previous study in monkeys and rabbits had proved that the dye of ICGA was exuded and the CVH was formed due to vascular endothelial damage, 49 suggested that CVH[+] exhibits vessel abnormalities at the innermost choroid.…”

Section: Discussionmentioning

confidence: 92%

The Morphological Characteristics of Choriocapillaris In the Fellow Eyes of Polypoidal Choroidal Vasculopathy.Co-authors

Wu¹,

Sugano²,

Itagaki³

et al. 2021

Preprint

View full text Add to dashboard Cite

To evaluate the morphological characteristics of the flow void (FV) in the fellow eyes of the unilateral polypoidal choroidal vasculopathy (PCV). 52 eyes of PCV fellow eyes (PCVF) and 57 age-matched normal controls were recruited in this prospective study. The number of FV was analyzed according to the size which from 6×6-mm swept source optical coherence tomography angiography scans. We used indocyanine green angiography images to determine whether choroidal vascular hyperpermeability (CVH) has occurred. For the PCVF, the incidence of CVH was 70% (35 of 50. Two of participants were allergic to the dye.) The number of FV significantly lower in all sizes (P = .002), 400 ~ 500µm2 (P = .002), 525 ~ 625µm2 (P = .002) and 650 ~ 750µm2 (P = .005). And the distribution significantly different in all sizes (P = .002), 400 ~ 500µm2 (P = .001), 525 ~ 625µm2 (P = .002) and 650 ~ 750µm2 (P = .001) compared to the controls. And showed no differences in the size from 775 to 1125µm2 between two groups. The area under the receiver operating characteristic curve of PCVF with CVH and controls was 0.93 (95% CI: 0.88 ~ 0.98) (P < .001). We found that the FV is a useful predictor for distinguishing the fellow eyes of PCV from normal eyes.

show abstract

Pachychoroid spectrum disease

Cited by 61 publications

References 198 publications

Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity

Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

The Morphological Characteristics of Choriocapillaris In the Fellow Eyes of Polypoidal Choroidal Vasculopathy.Co-authors

Contact Info

Product

Resources

About